FADS2 and ovarian carcinoma: Further investigations revealed that the inhibition of SCD1/FADS2 in ascites-derived ovarian cancer cells led to the downregulation of GPX4 and a decrease in GSH levels, which subsequently induced lipid peroxidation and mitochondrial dysfunction, triggered cellular ferroptosis, and heightened sensitivity to cisplatin 45.